RWM
MIRM icon

Raffa Wealth Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Raffa Wealth Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-32
Closed -$623 – 1184
2022
Q2 		$623 Buy
+32
New +$755 ﹤0.01% 962

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Raffa Wealth Management's MIRM Position: Q3 2022 in Review

Raffa Wealth Management sold out of Mirum Pharmaceuticals (MIRM) in Q3 2022, closing a stake of 32 shares — an estimated $623 sold.

Raffa Wealth Management first reported a position in MIRM in Q2 2022 and held it in 1 quarter. The position peaked at $623 in Q2 2022. 112 funds tracked by Wall St. Rank hold MIRM as of Q3 2022.

  • Raffa Wealth Management reported no remaining Mirum Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Raffa Wealth Management sold 32 Mirum Pharmaceuticals shares in Q3 2022, an estimated $623.
  • Raffa Wealth Management first reported a position in Mirum Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Raffa Wealth Management's Mirum Pharmaceuticals position peaked at $623 in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2022.

Based on Raffa Wealth Management's 13F filing for Q3 2022, filed 27 Jul 2026.